Limited data exist on the effects of induction treatment in patients with newly diagnosed multiple myeloma (NDMM) and renal impairment (RI), who may also be ineligible for autologous stem cell transplant. This analysis investigated the impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on renal function in patients from the Connect® MM Registry based on transplant status. Eligible patients were aged ≥18 years with symptomatic MM diagnosed ≤2 months before enrollment. Patients in this analysis received front-line RVd for ≥3 cycles and were grouped by transplant status and baseline renal function. As of August 4, 2021, 344 transplanted and 289 non-transplanted patients had received RVd for ≥3 cycles at induction. Improved renal function was observed at 3, 6, and 12 months in patients with all severities of RI at baseline. In patients with >60 and ≤60 creatinine clearance mL/min at baseline, median progression-free survival was 49.4 months and 47.6 months in transplanted patients and 35.7 months and 29.1 months in non-transplanted patients, respectively. These results provide real-world evidence that patients with NDMM and RI who receive front-line RVd for ≥3 cycles may have improved renal function regardless of transplant status, with renal function no longer affecting the long-term outcome. Clinical trial information: NCT01081028.
关于新诊断多发性骨髓瘤（NDMM）伴肾功能不全（RI）患者的诱导治疗效果数据有限，这些患者可能也不适合自体干细胞移植。本研究基于移植状态，调查了来自Connect® MM注册研究的患者中，来那度胺-硼替佐米-地塞米松（RVd）诱导治疗对肾功能的影响。合格患者年龄≥18岁，在入组前≤2个月诊断为有症状的多发性骨髓瘤。本分析中的患者接受了一线RVd治疗≥3个周期，并根据移植状态和基线肾功能进行分组。截至2021年8月4日，有344名移植患者和289名非移植患者在诱导期间接受了≥3个周期的RVd治疗。在基线时所有严重程度的肾功能不全患者中，在3、6和12个月时均观察到肾功能改善。在基线肌酐清除率>60和≤60 mL/min的患者中，移植患者的中位无进展生存期分别为49.4个月和47.6个月，非移植患者分别为35.7个月和29.1个月。这些结果提供了真实世界证据，表明接受一线RVd治疗≥3个周期的NDMM伴RI患者，无论移植状态如何，肾功能均可能改善，且肾功能不再影响长期结局。临床试验信息：NCT01081028。
肿瘤(癌症)患者之家